Minimizing the risk of hypoglycemia in patients with type 2 diabetes mellitus
Pamela KushnerUniversity of California, Irvine College of Medicine, California, USAAbstract: Hypoglycemia is a major barrier to achieving glycemic goals in patients with diabetes. Both acute and chronically recurrent hypoglycemic events appear to have long-term consequences for patients with type 2...
Guardado en:
Autor principal: | |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://doaj.org/article/1eca60a17676493fb776e45358fb1ef9 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:1eca60a17676493fb776e45358fb1ef9 |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:1eca60a17676493fb776e45358fb1ef92021-12-02T00:58:19ZMinimizing the risk of hypoglycemia in patients with type 2 diabetes mellitus1178-7007https://doaj.org/article/1eca60a17676493fb776e45358fb1ef92010-04-01T00:00:00Zhttps://www.dovepress.com/minimizing-the-risk-of-hypoglycemia-in-patients-with-type-2-diabetes-m-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Pamela KushnerUniversity of California, Irvine College of Medicine, California, USAAbstract: Hypoglycemia is a major barrier to achieving glycemic goals in patients with diabetes. Both acute and chronically recurrent hypoglycemic events appear to have long-term consequences for patients with type 2 diabetes mellitus (T2DM). Chronically recurrent hypoglycemia may lead to an impairment of the counterregulatory system, with the potential for the development of hypoglycemia unawareness syndrome, increased severe hypoglycemia-associated hospitalization, and increased mortality. Hypoglycemic events may also have negative implications in cardiovascular disease and/or dementia. Avoidance of hypoglycemia by treating with appropriate, individualized regimens for patients with T2DM should be a primary focus of physicians. Utilizing traditional agents (eg, metformin and thiazolidinediones) that do not promote hypoglycemia, in combination with newer agents such as dipeptidyl peptidase-4 inhibitors and incretin mimetics, could offer a therapeutic advantage when trying to help patients reach their hemoglobin A1c goal without the added risk of hypoglycemia.Keywords: hypoglycemia, type 2 diabetes mellitus, incretin, dipeptidyl peptidase-4 inhibitors, diabetes managementKushner PDove Medical PressarticleHypoglycemiatype 2 diabetes mellitusincretindipeptidyl peptidase-4 inhibitorsdiabetes managementSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 3, Pp 49-53 (2010) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
Hypoglycemia type 2 diabetes mellitus incretin dipeptidyl peptidase-4 inhibitors diabetes management Specialties of internal medicine RC581-951 |
spellingShingle |
Hypoglycemia type 2 diabetes mellitus incretin dipeptidyl peptidase-4 inhibitors diabetes management Specialties of internal medicine RC581-951 Kushner P Minimizing the risk of hypoglycemia in patients with type 2 diabetes mellitus |
description |
Pamela KushnerUniversity of California, Irvine College of Medicine, California, USAAbstract: Hypoglycemia is a major barrier to achieving glycemic goals in patients with diabetes. Both acute and chronically recurrent hypoglycemic events appear to have long-term consequences for patients with type 2 diabetes mellitus (T2DM). Chronically recurrent hypoglycemia may lead to an impairment of the counterregulatory system, with the potential for the development of hypoglycemia unawareness syndrome, increased severe hypoglycemia-associated hospitalization, and increased mortality. Hypoglycemic events may also have negative implications in cardiovascular disease and/or dementia. Avoidance of hypoglycemia by treating with appropriate, individualized regimens for patients with T2DM should be a primary focus of physicians. Utilizing traditional agents (eg, metformin and thiazolidinediones) that do not promote hypoglycemia, in combination with newer agents such as dipeptidyl peptidase-4 inhibitors and incretin mimetics, could offer a therapeutic advantage when trying to help patients reach their hemoglobin A1c goal without the added risk of hypoglycemia.Keywords: hypoglycemia, type 2 diabetes mellitus, incretin, dipeptidyl peptidase-4 inhibitors, diabetes management |
format |
article |
author |
Kushner P |
author_facet |
Kushner P |
author_sort |
Kushner P |
title |
Minimizing the risk of hypoglycemia in patients with type 2 diabetes mellitus |
title_short |
Minimizing the risk of hypoglycemia in patients with type 2 diabetes mellitus |
title_full |
Minimizing the risk of hypoglycemia in patients with type 2 diabetes mellitus |
title_fullStr |
Minimizing the risk of hypoglycemia in patients with type 2 diabetes mellitus |
title_full_unstemmed |
Minimizing the risk of hypoglycemia in patients with type 2 diabetes mellitus |
title_sort |
minimizing the risk of hypoglycemia in patients with type 2 diabetes mellitus |
publisher |
Dove Medical Press |
publishDate |
2010 |
url |
https://doaj.org/article/1eca60a17676493fb776e45358fb1ef9 |
work_keys_str_mv |
AT kushnerp minimizingtheriskofhypoglycemiainpatientswithtype2diabetesmellitus |
_version_ |
1718403369656123392 |